Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Acute breathlessness in lung cancer

Avinash Aujayeb, Jonathan Miller, Iain Matthews
Breathe 2014 10: 323-328; DOI: 10.1183/20734735.011214
Avinash Aujayeb
Respiratory Department, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aujayeb@doctors.net.uk
Jonathan Miller
Respiratory Department, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iain Matthews
Respiratory Department, Wansbeck General Hospital, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Case history

A 72-year-old woman with a World Health Organization (WHO) performance status of 1 presented in October 2013 with a left upper-lobe mass (fig. 1). She was an ex-smoker and a computed tomography (CT) scan showed a large mass at the left hilum (fig. 2) as well as a pulmonary embolus and a positron emission tomography (PET) scan staged the disease at T4N3M1b, with contralateral mediastinal lymphadenopathy and pelvic bone metastases. Biopsies from bronchcoscopy showed an adenocarcinoma and epidermal growth factor receptor (EGFR) mutation was negative. She underwent four cycles of palliative chemotherapy with good radiological and clinical response (fig. 3) and was started on warfarin.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Initial presentation showed a left upper-lobe mass

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

CT showing large mass at the left hilum

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

After four cycles of chemotherapy, there was good response

At follow-up in August 2014, progressive disease was noted radiologically (figs 4, 5 and 6) and palliative radiotherapy was thus considered for vertebral pain and then second-line chemotherapy.

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

CT at follow-up

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

CT at follow-up

Figure 6
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6

CT at follow-up

Task 1

What do the computed tomography images show (figs 4, 5 and 6) ?

1. A small left effusion with an enlarging mass at the left hilum

2. A small pericardial effusion

3. Some degree of left upper-lobe collapse

4. All of the above

Answer 1

4. All of the above

She presented to the ambulatory care department via primary care with a high international normalisation ratio, probably due to the recent prescription of antibiotics for a presumed lower respiratory tract infection. At that point, she complained of increasing breathlessness and a chest radiograph was performed. Her oxygen saturation was 89% on 60% oxygen via a Venturi mask, she was normotensive but tachycardic at 130 beats·min−1. Electrocardiography showed a sinus tachycardia. Her white cell count was normal and inflammatory markers such as C-reactive protein only mildly raised at 31 mg·L−1. Her international normalised ratio (INR) was 2.3. Her chest was clear to auscultation and her heart sounds were normal. She was treated empirically for a presumed pneumonia with intravenous fluids and antibiotics.

Figure 7
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7

Chest radiograph at admission to the ambulatory care department

Task 2

What new finding does the admission chest radiograph in figure 7 show?

1. Significant right middle lobe consolidation

2. A left-sided pneumothorax

3. A large pericardial effusion

4. All of the above

Answer 2

3. A large pericardial effusion

Task 3

What is the likely cause of her pericardial effusion?

1. Pericardial bleeding due to high INR

2. Atypical infection due to immunosuppression

3. Malignant disease

4. Autoimmune disease

Answer 3

3. Malignant disease

In areas of low tuberculosis prevalence, such as the North East of England, where our patient lived, large pericardial effusions are commonly due to malignancy. In various studies, the prevalence of malignant disease in pericardial disease was up to 60% [1–4]. Lung cancer is the most common disease causing malignant pericardial effusion (MPE) although case reports of breast and oesophageal cancers, leukaemia, lymphomas and melanomas exist [2]. Large autopsy studies of patients dying of metastatic cancer showed that the prevalence of any cardiac involvement is 11–20% and, of those, about 30% had a pericardial effusion [5]. Development of an MPE suggests metastatic disease via direct or indirect spread. However, other causes need to be kept in mind in a patient with cancer developing a pericardial effusion such as thoracic irradiation causing a radiation-induced pericarditis and subsequent fluid build-up or immunocompromise due to chemotherapy predisposing to infective aetiologies.

A diagnosis of cardiac tamponade was thus made.

Task 4

What signs cannot be expected to be seen in a patient with cardiac tamponade?

1. Collapsing pulse

2. Pulsus paradoxus

3. Pulsus alternans

4. Quiet heart sounds

Answer 4

1. Collapsing pulse

Cardiac tamponade arises due to equalisation of cardiac pressures leading to impaired biventricular filling. The pericardial sack has some elasticity which is quickly reached with fluid accumulation. Cardiac volume becomes smaller during systole and venous return shifts to cardiac systole to reduce cardiac output. Normally, systemic venous return to the right side of the heart increases with inspiration and pulmonary venous return to the left heart decreases with inspiration so that systemic arterial pressure normally falls by <10 mmHg during inspiration.

In cardiac tamponade, the rigid pericardium prevents the free wall from expanding. Thus, the distension of the right ventricle is limited to the interventricular septum and this causes the septum to bulge to the left, reducing left ventricular compliance and contributing to further decreased filling of the left ventricle during inspiration. This leads to an exaggerated drop in systolic blood pressure in inspiration called pulsus paradoxus. Our patient was too sick to allow the proper measurement of this sign.

Thus, most of her symptoms and signs (breathlessness, tachycardia, hypotension and decreased capillary refill time peripherally) could be directly attributable to pericardial tamponade. The electrocardiogram showed small complexes but no pulsus alternans, which is where the QRS complexes alternate between large and small with each beat.

The patient was admitted to the local hospital, where there was no cardiology cover out of hours. Her high INR also precluded her having an immediate intervention. She was given Vitamin K, an antagonist of warfarin, oxygen and fluids and was thus optimised for a drain the next day.

Task 5

What is not the next appropriate step?

1. Urgent referral to cardiology for a pericardial drain

2. Oxygen to keep saturations between 88-92%

3. Discussion with family and patient re escalation of care and do not resuscitate order

4. Reversal of high INR with vitamin K

Answer 5

1. Urgent referral to cardiology for a pericardial drain

MPEs carry a very poor prognosis. When due to lung cancer, some series have put the life expectancy at 3 months [6] Our patient’s WHO performance status had deteriorated significantly to 4 (WHO performance status of 4 means that the patient is bed-bound and cannot carry out self care) and, as such, at that moment in time, her risk of mortality was very high. As such, a treatment escalation plan was put in place and a do not resuscitate order was instituted. The patient and her family were in full agreement. Her INR was too high for any procedure to be performed and so 2 mg of vitamin K was given intravenously. Our hospital is a district general hospital with no cardiology cover out of hours, and she had presented on a Sunday, but we did not think that an urgent cardiology opinion should be sought from the tertiary centre.

The patient was thus admitted locally. Her high INR also precluded her having an immediate intervention. She was given vitamin K, an antagonist of warfarin, oxygen and fluids and was thus optimised for a drain the next day.

Conclusion

The next day, an echocardiogram showed a large pericardial effusion and with an INR of 1.8, a pericardial drain was inserted. 2 L of heavily blood-stained fluid was drained, with significant improvement in the patient’s haemodynamic and respiratory status over the next 24 h. She was eventually discharged home 48 h later, not requiring any oxygen and with a WHO performance status of 2 (which means that a patient is symptomatic but is up and about more than 50% of waking hours). Figure 8] shows her chest radiograph just prior to discharge.

Figure 8
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 8

Radiograph just prior to discharge

Recurrence of her MPE was briefly discussed and it was felt that she was not suitable for referral for a pericardial window at this moment in time. We felt the effusion was malignant as its development was noted in hindsight on the previous CT scans rather than a reactive one due to her over anticoagulation. Unfortunately, no fluid was sent for cytology testing. 4 weeks after her discharge, a marked deterioration was noted by the patient's general practitioner and full palliative measures were instituted. The patient passed away peacefully in her own home.

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2014

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Maisch B,
    2. Ristic A,
    3. Pankuweit S
    . Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 2010; 53: 157–163.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Wilkes JD,
    2. Fidias P,
    3. Vaickus L,
    4. et al
    . Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer 1995; 76: 1377–1387.
    OpenUrlCrossRefPubMed
    1. Gornik HL,
    2. Gerhard-Herman M,
    3. Beckman JA
    . Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005; 23: 5211–5216.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Porte HL,
    2. Janecki-Delebecq TJ,
    3. Finzi L,
    4. et al
    . Pericardoscopy for primary management of pericardial effusion in cancer patients. Eur J Cardiothorac Surg 1999; 16: 287–291.
    OpenUrl
  4. ↵
    1. Abraham KP,
    2. Reddy V,
    3. Gattuso P
    . Neoplasms metastatic to the heart: review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 1990; 3: 195–198.
    OpenUrlPubMed
  5. ↵
    1. Cullinane CA,
    2. Paz IB,
    3. Smith D,
    4. et al
    . Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 2004; 125: 1328–1329.
    OpenUrl
View Abstract
PreviousNext
Back to top
Vol 10 Issue 4 Table of Contents
Breathe: 10 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acute breathlessness in lung cancer
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Acute breathlessness in lung cancer
Avinash Aujayeb, Jonathan Miller, Iain Matthews
Breathe Dec 2014, 10 (4) 323-328; DOI: 10.1183/20734735.011214

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Acute breathlessness in lung cancer
Avinash Aujayeb, Jonathan Miller, Iain Matthews
Breathe Dec 2014, 10 (4) 323-328; DOI: 10.1183/20734735.011214
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Case history
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Lung cancer
  • Lung imaging
  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung cancer screening by volume CT
  • In pursuit of the primary
  • A rare complication in a case of nonsmall cell lung carcinoma
Show more Expert opinion

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society